Table 3.
Baseline characteristics of patients treated with entecavir (ETV) or lamivudine (LAM) according to HBeAg status.
| ETV group | LAM group | |||
|---|---|---|---|---|
| HBeAg | Positive | Negative | Positive | Negative |
| Number | 84 | 69 | 62 | 79 |
| Age (years) | 48 ± 12 | 56 ± 11* | 44 ± 11 ## | 54 ± 11** |
| Gender (male) | 53 | 45 | 48 | 52** |
| HBV DNA (log IU/mL) | 7.5 ± 1.1 | 5.7 ± 1.5* | 6.9 ± 1.1$ | 5.9 ± 1.3** |
| ALT (IU/L) | 219 ± 325 | 159 ± 246 | 309 ± 334 | 154 ± 174** |
| US: Cirrhosis (+) | 25 | 29 | 16 | 41 |
| Periods to undetectable HBV DNA (months) | 8.3 ± 10.5 | 7.3 ± 11.0 | 15.0 ± 24.7$$ | 7.5 ± 16.9# |
Data are expressed as mean ± SD. HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; US, ultrasound findings; *P < 0.001, compared to HBeAg-positive of ETV group; **P < 0.001 and #P = 0.034, compared to HBeAg-positive of LAM group; ##P = 0.041, $P = 0.001 and $$P = 0.027, compared to HBeAg-positive of ETV group.